Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn about a recent article by Eugenio Galli at al, adding:
“New data on seizure prophylaxis in CAR-T!
A new study evaluated whether levetiracetam (LVT) prevents ICANS in patients receiving anti-CD19 CAR-T for LBCL. Using a propensity-matched cohort of 254 patients, the findings were clear:
No reduction in ICANS with LVT prophylaxis
- Any-grade ICANS: 32.3% vs 37.1% (ns)
- Severe ICANS (G2–4): 15.1% vs 16.1% (ns)
BUT: LVT was linked to higher early hematotoxicity (ICAHT)
- G2–4 ICAHT: 37.3% → 63.9% (P < .001)
No differences in OS, PFS, or non-relapse mortality.
Takeaway: Routine LVT prophylaxis does not prevent ICANS and may increase toxicity. More work needed to define if/when it should be used.”
Title: Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study
Authors: Eugenio Galli, Roberta Di Blasi, Alice Di Rocco, Caterina Cristinelli, Ilaria Pansini, Côme Bommier, Alessandro Corrente, Ilenia De Bernardis, Marcello Viscovo, Stefan Hohaus, Anna Modoni, Federica Sorà, Patrizia Chiusolo, Maurizio Martelli, Simona Sica, Catherine Thieblemont
Read the Full Article on Blood Advances
More posts featuring Yan Leyfman.